Documentation Centre

July 24, 2020
The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease? Curr Opin Lipidol. 2020;31:140-146.
Reeskamp LF, Tromp TR, Stroes ESG

Description of this Publication

Consult publication on external website

By clicking on this link, you will leave the INTERNATIONAL CHAIR ON CARDIOMETABOLIC RISK website

Key Words
Cardiovascular Disease, Lipids/Lipoproteins, Prevention